Stock Financial Ratios, Dividends, Split History

MHK / Mohawk Industries, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)17,379.11
Enterprise Value ($M)21,269.34
Book Value ($M)7,337.94
Book Value / Share98.37
Price / Book2.46
NCAV ($M)-886.40
NCAV / Share-11.88
Price / NCAV-17.73
Share Statistics
Common Shares Outstanding 74,425,467
Weighted Average Number Of Diluted Shares Outstanding 74,839,000
Weighted Average Number Diluted Shares Outstanding Adjustment 482,000
Weighted Average Number Of Shares Outstanding Basic 74,357,000
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.09
Return on Assets (ROA)0.10
Return on Equity (ROE)0.17
Balance Sheet (mrq) ($M)
Quick Ratio0.81
Current Ratio1.54
Income Statement (mra) ($M)
Sales Revenue Goods Net9,491,290,000.00
Operating Income1,354.17
Net Income974.69
Earnings Per Share Diluted12.98
Earnings Per Share Basic13.07
Cash Flow Statement (mra) ($M)
Cash From Operations1,193.60
Cash from Investing-1,240.70
Cash from Financing-1,240.70
Identifiers and Descriptors
Central Index Key (CIK)851968
Related CUSIPS
608190904 060819010 608190954
Industry Groups
SIC 2273 - Carpets and Rugs

Split History

Stock splits are used by Mohawk Industries, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

7h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

8h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

Mohawk Industries: Strong Fundamentals And Insider Buying Make This An Interesting Pick

2018-06-15 seekingalpha
Mohawk Industries is a Georgia-based company that designs, manufactures, and distributes flooring products such as tiles, carpets, rugs, hardwood flooring, and so on.

Is Mohawk (MHK) a Great Stock for Value Investors?

2018-06-04 zacks
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?

Tracking Ruane, Cunniff & Goldfarb's Portfolio - Q1 2018 Update

2018-05-28 seekingalpha
Ruane, Cunniff & Goldfarb’s 13F portfolio value decreased ~11% from $12.20B to $10.91B. The number of positions decreased from 66 to 59. (756-0)

Mohawk Industries (MHK) Down 6.5% Since Earnings Report: Can It Rebound?

2018-05-28 zacks
It has been about a month since the last earnings report for Mohawk Industries, Inc. (MHK - Free Report) . Shares have lost about 6.5% in that time frame. (11-0)

Tracking Larry Robbins' Glenview Capital Management Portfolio - Q1 2018 Update

2018-05-25 seekingalpha
Glenview Capital Management’s 13F portfolio value decreased from $18.50B to $17.10B this quarter. The number of positions decreased from 58 to 52. (888-1)

CUSIP: 608190104